Accelerate to discover

Back to filter

Related topics

Centrifugation of suspension cells is a problem!

Curiox

Jul 8, 2020

Do you think that centrifuging cells at 500 x g is not going to cause issues? Moreover, sample prep involving...

IncuCyte webinar: Advances in 3D cell models for cancer biology

Sartorius

Jul 1, 2020

Get answers to your questions on 3D spheroid-based drug discovery, organoid research and working with advanced cell...

Bruker MicroCT systems supporting quality control for refurbished FFP masks

Bruker Biospin

Jun 29, 2020

In the effort to tackle the coronavirus pandemic, Bruker is proud that its instruments are being used to ensure quality...

Advance your Neuro-Oncology applications with IncuCyte

Sartorius

Jun 25, 2020

Neuro-oncology research can benefit from robust translational in vitro models to gain greater understanding of brain...

Jul 11, 2020

MicroCT Applications in Lung research and Immunology

Bruker Biospin

Jun 22, 2020

The ability to monitore and quantitate lung disease in real time is an advantage to using small animal microCT. Also,...

Imaging Extracellular Vescicles with super-resolution microscopy

ONI

Jun 18, 2020

Extracellular vesicles (EVs) play key roles in cell-to-cell communication. EVs can cross biological barriers (such as...

The Role of Micro-CT in Imaging Breast Cancer Specimens

Bruker Biospin

Jun 17, 2020

The goal of breast cancer surgery is to remove all of the cancer with a minimum of normal tissue, but absence of full...

Jul 11, 2020

Bruker´s micro-CT used for some of the World’s First in vivo COVID-19 Imaging Experiments

Bruker Biospin

Jun 9, 2020

Bruker's BioSpin PreClinical Imaging Division reports the use of the Bruker SkyScan 1278 in vivo micro-CT system at the...

Show all topics (10)

Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer

Jun 1, 2018

The 10‐year survival rate of cancer patients has greatly increased over the last 20 years. However, the survival rate of patients with major malignant tumors, such as lung and pancreatic cancers, still shows negligible improvement.The conventional chemotherapeutic strategy for treating lung cancer remains unsatisfactory in this respect. Specifically, the 5‐year survival rates of both non‐small‐cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients exhibited merely 4–5% improvements in the past decade for cancer in stages I–III.2 The main difficulty in treating lung cancer is the lack of targeted chemotherapeutic agents specific to the lung tumor tissues and, thus, non‐specific targeting generally leads to unwanted side effects induced by excessive doses of chemotherapeutic agents.

Several strategies have been introduced to resolve the aforementioned issues, such as cancer antigen‐targeted monoclonal antibody (mAb) therapy,4 nanodrug delivery,5 and cell‐mediated therapy (i.e., T‐cell‐based therapy for NSCLC6). However, many clinical trials have shown that intravenously administered mAb, particularly epidermal growth factor receptor‐targeting mAbs, induced dermatological toxicities (e.g., acneiform eruption, xerosis, telangiectasia, hyperpigmentation, fissures, and hair/nail changes) in over 50% of patients after treatment.

Read more!

Scientific paper
Application

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Yokogawa

Yokogawa is a leading provider of confocal quantitative live cell imaging platforms. Combining superior technology with engineering services, project management, and maintenance, Yokogawa delivers field proven operational efficiency, safety, quality, and reliability. 

Related products

Confocal quantitative image cytometer CQ1 offers a new approach to image quantification

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey